Conclusion of MOU with Clinical Research Coordinator of the Ministry of Health of Republic of Indonesia

Remedy & Company Corporation (Located in Chiyoda-ku, Tokyo, Japan; Group CEO: Masakuni Ukita, hereinafter referred to as “We”), have concluded a Memorandum of Understanding (MOU) with the Clinical Research Coordinator of the Ministry of Health of the Republic of Indonesia with respect to establishing a collaborative system for the development of pharmaceutical product in the country.

The Clinical Research Coordinator INDONESIA (hereinafter “INA CRC”), whom we have contracted the MOU with, was established under Ministry of Health with the aim of promoting clinical trials in Indonesia.
With our vast network and extensive experience in clinical trials not only locally in Japan but also across numerous countries in Asia, we strongly believe such collaboration is a great opportunity to bring about promoting clinical trials in Indonesia and introducing Japan-stemmed clinical trials in the country as well.

As a leading player in the field of infectious disease, our goal has always been to create a clinical trial platform to enable speedy development of safe and effective vaccines and medications for infectious diseases in the Global South while increase the values and options of services available to our clients.
While we, Remedy and Company, continue to contribute to drug innovation in Japan via promotion of Japan-stemmed clinical trials, we will strive to strengthen the development of vaccine and treatment for existing infectious disease in various countries of the world, so that a readiness level to handle the Next pandemic is achieved.